Johnson & Johnson (JNJ) Other Working Capital Changes (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Other Working Capital Changes came in at -$349.0 million in Q1 2026, down 126.5% year-on-year from $1.3 billion in Q1 2025, and up 76.51% quarter-over-quarter from -$1.5 billion in Q4 2025.
Johnson & Johnson (JNJ) Other Working Capital Changes (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Other Working Capital Changes across 18 years of filings, most recently posting -$349.0 million for Q1 2026.
- Other Working Capital Changes for Q1 2026 came in at -$349.0 million, down 126.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.5 billion (up 60.81% YoY), and the FY2025 annual result was $6.2 billion, up 459.17% from the prior year.
- Other Working Capital Changes came in at -$349.0 million for Q1 2026 at Johnson & Johnson, up from -$1.5 billion in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of $4.9 billion in Q2 2025 to a low of -$3.2 billion in Q1 2024.
- The 5-year median for Other Working Capital Changes is $229.0 million (2023), against an average of $532.1 million.
- Peak annual rise in Other Working Capital Changes reached 1153.15% in 2024, while the deepest fall reached 449.62% in 2024.
- Johnson & Johnson's Other Working Capital Changes stood at -$995.0 million in 2022, then soared by 312.46% to $2.1 billion in 2023, then plunged by 136.33% to -$768.0 million in 2024, then tumbled by 93.49% to -$1.5 billion in 2025, then surged by 76.51% to -$349.0 million in 2026.
- The last three Other Working Capital Changes figures came in at -$349.0 million (Q1 2026), -$1.5 billion (Q4 2025), and $1.5 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | -349.00 Mn |
| Mar 29, 2026 | -349.00 Mn |
| Dec 28, 2025 | -1.49 Bn |
| Dec 28, 2025 | -1.49 Bn |
| Sep 28, 2025 | 1.46 Bn |
| Sep 28, 2025 | 1.46 Bn |
| Jun 29, 2025 | 4.88 Bn |
| Jun 29, 2025 | 4.88 Bn |
| Mar 30, 2025 | 1.32 Bn |
| Mar 30, 2025 | 1.32 Bn |
| Dec 29, 2024 | -768.00 Mn |
| Dec 29, 2024 | -768.00 Mn |
| Sep 29, 2024 | 2.78 Bn |
| Sep 29, 2024 | 2.78 Bn |
| Jun 30, 2024 | -532.00 Mn |
| Jun 30, 2024 | -532.00 Mn |
| Mar 31, 2024 | -3.20 Bn |
| Mar 31, 2024 | -3.20 Bn |
| Dec 31, 2023 | 2.11 Bn |
| Dec 31, 2023 | 2.11 Bn |